Therapeutic strategies in early rheumatoid arthritis

Best Practice and Research: Clinical Rheumatology

Volumn 19, Issue 1, 2005, Pages 163-177

  Smolen, Josef S ^a,b   Aletaha, Daniel ^a   Machold, Klaus P ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b GENERAL HOSPITAL LINZ   (Austria)

Author keywords

Anti RA33 anticyclic citrullinated peptide; Antitumour necrosis factor; Biological agents; Combination therapy; Disease activity; DMARDs; Early arthritis; Methotrexate; Remission; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

ANTIRHEUMATIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; GLUCOCORTICOID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY;

ARTHRALGIA; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; EARLY DIAGNOSIS; HUMAN; JOINT RADIOGRAPHY; MONOTHERAPY; PATIENT REFERRAL; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ALGORITHMS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EARLY DIAGNOSIS; HUMANS; RHEUMATOLOGY;

EID: 10844231021     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2004.08.009     Document Type: Review

References (102)

1. K.W. Drossaers-Bakker M. de Buck D. van Zeben et al. Long-term course and outcome of functional capacity in rheumatoid arthritis: The effect of disease activity and radiologic damage over time Arthritis Rheum 42 1999 1854-1860
2. D.L. Scott K. Pugner K. Kaarela et al. The links between joint damage and disability in rheumatoid arthritis Rheumatology (Oxford) 39 2000 122-132
3. M.J. Plant P.W. Jones J. Saklatvala et al. Patterns of radiological progression in rheumatoid arthritis: Results of an 8 year prospective study J Rheumatol 25 1998 417-426
4. D.M. Van der Heijde Joint erosions in patients with early rheumatoid arthritis Br J Rheumatol 34 supplement 2 1995 74-78
5. K.P. Machold T.A. Stamm G.J.M. Eberl et al. Very recent onset arthritis-clinical, laboratory and radiological findings during the first year of disease J Rheumatol 29 2002 2278-2287
6. P.L. Lipsky D.M.F.M. van der Heijde E.W. St. Clair et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis N Engl J Med 343 2000 1594-1602
7. L. Klareskog D. van der Heijde J.P. de Jager et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial Lancet 363 2004 675-681
8. A. Van der Heide J.W.G. Jacobs J.W.J. Bjilsma et al. The effectiveness of early treatment with 'second-line' antirheumatic drugs: A randomized, controlled trial Ann Intern Med 124 1996 707
9. A.A. Stenger M.A. van Leeuwen P.M. Houtman et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression Br J Rheumatol 37 1998 1157-1163
10. T. Möttönen P. Hannonen M. Leirisalo-Repo et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial Lancet 353 1999 1568-1573
11. L.R. Lard H. Visser I. Speyer et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: Comparison of two cohorts who received different treatment strategies Am J Med 111 2001 446-451
12. V. Nell K.P. Machold G. Eberl et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis Rheumatology (Oxford) 43 2004 906-917
13. F.C. Arnett S.M. Edworthy D.A. Block et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 1988 315-324
14. B.J. Harrison D.P. Symmons E.M. Barret A.S. Silman The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis J Rheumatol 25 1998 2330
15. N. Wiles D.P. Symmons B. Harrison et al. Estimating the incidence of rheumatoid arthritis: Trying to hit a moving target? Arthritis Rheum 42 1999 1339-1346
16. M.W. Ropes G.A. Bennett S. Cobb et al. 1958 revision of diagnostic criteria for rheumatoid arthritis Arthritis Rheum 2 1959 16-20
17. M. Green H. Marzo-Ortega D. McGonagle et al. Persistence of mild, early inflammatory arthritis: The importance of disease duration, rheumatoid factor, and the shared epitope Arthritis Rheum 42 1999 2184-2188
18. E.J. Tunn P.A. Bacon Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic Br J Rheumatol 32 1993 97-103
19. M. Bukhari M. Lunt B.J. Harrison et al. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: Results from the Norfolk Arthritis Register Study, a large inception cohort Arthritis Rheum 46 2002 906-912
20. D. Aletaha G. Eberl V.P. Nell et al. Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: Results from two matched questionnaires within three years Ann Rheum Dis 61 2002 630-634
21. G. Steiner J.S. Smolen Autoantibodies in rheumatoid arthritis and their clinical significance Arthritis Res 4 supplement 2 2002 S1-S5
22. N. Wiles G. Dunn E. Barrett et al. Associations between demographic and disease-related variables and disability over the first five years of inflammatory polyarthritis: A longitudinal analysis using generalized estimating equations J Clin Epidemiol 53 2000 988-996
23. H. Visser S. le Cessie K. Vos et al. How to diagnose rheumatoid arthritis early. A prediction model for persistent (erosive) arthritis Arthritis Rheum 46 2002 357-365
24. P. Emery F.C. Breedveld M. Dougados Early referral recommendation for newly diagnosed rheumatoid arthritis: Evidence based development of a clinical guide Ann Rheum Dis 61 2002 290-297
25. B.J. Harrison D.P. Symmons Early inflammatory polyarthritis: Results from the Norfolk Arthritis Register with a review of the literature. II. Outcome at three years Rheumatology (Oxford) 39 2000 939-949
26. D.P.M. Symmons J.M.W. Hazes A.J. Silman Cases of early inflammatory polyarthritis should not be classified as having rheumatoid arthritis J Rheumatol 30 2003 902-904
27. A.B. Hassell M.J. Davis P.D. Fowler et al. The relationship between serial measures of disease activity and outcome in rheumatoid arthritis Q J Med 86 1993 601-607
28. R.K. Mallya F.C. de Beer E.D. Hamilton et al. Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentrations of C-reactive protein and erythrocyte sedimentation rate J Rheumatol 9 1982 224-228
29. P.M. Welsing A.M. van Gestel H.L. Swinkels et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis Arthritis Rheum 44 2001 2009-2017
30. P.T. Dawes P.D. Fowler S. Clarke et al. Rheumatoid arthritis: Treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression Br J Rheumatol 25 1986 44-49
31. M.A. van Leeuwen M.H. van Rijswijk W.J. Sluiter et al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system J Rheumatol 24 1997 20-27
32. M.A. van Leeuwen D.M. van der Heijde M.H. van Rijswijk et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts and acute phase reactants J Rheumatol 21 1994 425-429
33. M. Boers P. Tugwell D.T. Felson et al. WHO and ILAR core endpoints for symptom modifying antirheumatic drugs in RA clinical trials J Rheumatol 21 supplement 41 1994 86-89
34. D.T. Felson J.J. Anderson M. Boers et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials Arthritis Rheum 36 1993 729-740
35. D.M.F.M. Van der Heijde M. van't Hof P.L. van Riel L.B.A. van de Putte Development of a disease activity score based on judgement in clinical practice by rheumatologists J Rheumatol 20 1993 579-581
36. J.S. Smolen The work of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials Br J Rheumatol 31 1992 219-220
37. D.L. Scott G.S. Panayi P.L.C.M. van Riel et al. Disease activity in rheumatoid arthritis-preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research Clin Exp Rheumatol 10 1992 521-525
38. D.T. Felson J.J. Anderson M. Boers et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum 38 1995 727-735
39. A.M. van Gestel M.L.L. Prevoo M.A. Van't Hof et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria Arthritis Rheum 39 1996 34-40
40. A.M. van Gestel P.L.C.M. van Riel Validation of rheumatoid arthritis improvement criteria that include simplified joint counts Arthritis Rheum 41 1998 1845-1850
41. A.M. van Gestel J.J. Anderson P.L.C.M. van Riel et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials J Rheumatol 26 1999 705-711
42. J.S. Smolen F.C. Breedveld M.H. Schiff et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice Rheumatology 42 2003 244-257
43. D. Van der Heijde L. Simon J. Smolen et al. How to report radiographic data in randomized clinical trials in rheumatoid arthritis: Guidelines from a roundtable discussion Arthritis Rheum 47 2002 215-218
44. J.F. Fries P.W. Spitz R.G. Kraines H.R. Holman Measurement of patient outcome in arthritis Arthritis Rheum 23 1980 137-145
45. T.T. Mottonen P.J. Hannonen M. Boers Combination DMARD therapy including corticosteroids in early rheumatoid arthritis Clin Exp Rheumatol 17 supplement 18 1999 S59-S65
46. P. Emery M. Salmon Early rheumatoid arthritis: Time to aim for remission? Ann Rheum Dis 54 1995 944-947
47. B.J. Harrison D.P. Symmons P. Brennanet al. Natural remission in inflammatory polyarthritis: Issues of definition and prediction Br J Rheumatol 35 1996 1096-1100
48. M.L. Prevoo A.M. van Gestel t' Hof MA van et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score Br J Rheumatol 35 1996 1101-1105
49. V.P.K. Nell K.P. Machold G. Eberl et al. The benefit of very early referral and therapy with disease modifying antirheumatic drugs in patients with early rheumatoid arthritis Arthritis Rheum 46 supplement 2002 S334
50. E.T. Molenaar A.E. Voskuyl H.J. Dinant et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission Arthritis Rheum 50 2004 36-42
51. D. Mulherin O. Fitzgerald B. Bresnihan Clinical improvement and radiological deteriorartion in rheumatoid arthritis: Evidence that pathogenesis of synovial inflammation and articular erosion may differ Br J Rheumatol 35 1996 1263-1268
52. S. ten Wolde F.C. Breedveld J. Hermans et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis Lancet 347 1996 347-352
53. R.S. Pinals A.T. Masi R.A. Larsen Preliminary criteria for clinical remission in rheumatoid arthritis Arthritis Rheum 24 1981 1308-1315
54. P.L. van Riel A.M. van Gestel Clinical outcome measures in rheumatoid arthritis Ann Rheum Dis 59 supplement 1 2000 i28-i31
55. R.H. Mullan B. Bresnihan Disease-modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritis Clin Exp Rheumatol 21 supplement 31 2003 S158-S164
56. L. Gossec M. Dougados P. Goupille et al. Prognostic factors for remission in early rheumatoid arthritis: A multiparameter prospective study Ann Rheum Dis 63 2004 675-680
57. J.S. Smolen D.M. van der Heijde P. Emery et al. Methotrexate naive early rheumatoid arthritis (RA) patients with higher baseline ESR and CRP derive greater radiographic benefit from initiating treatment with a combination of infliximab and methotrexate Arthritis Rheum 48 2004 3655
58. J. van Aken L.R. Lard S. leCessie Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis Ann Rheum Dis 63 2004 274-279
59. K. Puolakka H. Kautiainen T. Mottonen et al. Early control of disease activity maintains working capacity in early rheumatoid arthritis (RA) Ann Rheum Dis 61 supplement 1 2004 59
60. J.R. Kirwan The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group N Engl J Med 333 1995 142-146
61. D. Aletaha G. Eberl V.P.K. Nell et al. Early rheumatoid arthritis - survey on the changing concepts and attitudes from an international view between 1997 and 2003 Ann Rheum Dis 63 2004 in press
62. D.L. Scott D.P. Symmons B.L. Coulton A.J. Popert Long-term outcome of treating rheumatoid arthritis: Results after 20 years Lancet 1 1987 1108-1111
63. D.L. Mattey A.B. Hassell P.T. Dawes et al. Independent association of rheumatoid factor and the HLA-DRB1 shared epitope with radiographic outcome in rheumatoid arthritis Arthritis Rheum 44 2001 1529-1533
64. V.P.K. Nell K.P. Machold G. Eberl et al. The diagnostic and prognostic significance of autoantibodies in patients with very early arthritis Arthritis Rheum 48 supplement 2003 S197
65. J.L. Nelson C.E. Dugowson T.D. Koepsell et al. Rheumatoid factor, HLA-DR4, and allelic variants of DRB1 in women with recent-onset rheumatoid arthritis Arthritis Rheum 37 1994 673-680
66. A.J. Silman J.E. Pearson Epidemiology and genetics of rheumatoid arthritis Arthritis Res 4 supplement 3 2002 S265-S272
67. M.A. Quinn H. Marzo-Ortega S. Proudman et al. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol Arthritis Rheum 48 2003 3039-3045
68. A.A. van Everdingen J.W. Jacobs D.R. Siewertsz Van Reesema J.W. Bijlsma Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects: A randomized, double-blind, placebo-controlled clinical trial Ann Intern Med 136 2002 1-12
69. V. Strand L.S. Simon Low dose glucocorticoids in early rheumatoid arthritis Clin Exp Rheumatol 21 supplement 31 2003 S186-S190
70. H.A.M.R. Capell J.A. Hunter D. Porter et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: Results of a randomised controlled trial Ann Rheum Dis 63 2004 797-803
71. R.B.M. Landewe Treatment in early inflammatory arthritis: The SAVE initiative and the DINORA initiative Ann Rheum Dis 63 supplement 1 2004 48
72. M. Boers A.C. Verhoeven H.M. Markusse et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis: A randomised trial Lancet 350 1997 309-318
73. R. Rau G. Herborn H. Menninger O. Sangha Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients Rheumatology (Oxford) 41 2002 196-204
74. T. Mottonen P. Hannonen M. Korpela et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis Arthritis Rheum 46 2002 894-898
75. J.M. Bathon R.W. Martin R.M. Fleischmann et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl J Med 343 2000 1586-1593
76. M.M. Corkill B.W. Kirkham I.C. Chikanza et al. Intramuscular depot methylprednisolone induction of chrysotherapy in rheumatoid arthritis: A 24-week randomized controlled trial Br J Rheumatol 29 1990 274-279
77. J.J. Anderson D.T. Felson Factors predicting response to treatment in rheumatoid arthritis: The importance of disease duration Arthritis Rheum 43 2000 22-29
78. D. Aletaha J.S. Smolen The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses Rheumatology (Oxford) 41 2002 1367-1374
79. C. Egsmose B. Lund G. Borg et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study J Rheumatol 22 1995 2208-2213
80. K. Eberhardt L. Rydgren E. Fex et al. D-pencillamine in early rheumatoid arthritis: Experience from a 2-year double blind placebo controlled study Clin Exp Rheumatol 14 1996 625-631
81. R. Munro R. Hampson A. McEntergart et al. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: Results of a five year prospective study Ann Rheum Dis 57 1998 88-93
82. D.M. Van der Heijde P.L. van Riel I.H. Nuver-Zwart L.B. van de Putte Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up Lancet 335 1990 539
83. D.T. Felson J.J. Anderson R.F. Meenan Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A meta-analysis of published clinical trials Arthritis Rheum 35 1992 1117-1125
84. E.L. Matteson C.M. Weyand J.W. Fulbright et al. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to non-aggressive DMARD treatment and perspective from a 2-yr open label trial Rheumatology 2004
85. J.S. Smolen J.R. Kalden D.L. Scott et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial Lancet 353 1999 259-266
86. M. Dougados B. Combe A. Cantagrel et al. Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components Ann Rheum Dis 58 1999 220-225
87. D.T. Felson J.J. Anderson R.F. Meenan The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis Arthritis Rheum 37 1994 1487-1491
88. C.J. Haagsma P.L. van Riel A.J. de Jong L.B. van de Putte Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomized, controlled, double-blind, 52 week clinical trial Br J Rheumatol 36 1997 1082-1088
89. J.F. Maillefert B. Combe P. Goupille et al. Long term structural effects of combination therapy in patients with early rheumatoid arthritis: Five year follow up of a prospective double blind controlled study Ann Rheum Dis 62 2003 764-766
90. M. Dougados J.S. Smolen Pharmacological management of early rheumatoid arthritis - does combination therapy improve outcomes? J Rheumatol 66 2002 20-26
91. J. O'Dell Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications N Engl J Med 334 1996 1287-1291
92. R.B. Landewe M. Boers A.C. Verhoeven et al. COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention Arthritis Rheum 46 2002 347-356
93. J.K. De Vries-Bouwstra Y.P.M. Goekoop-Ruiterman D. Van Zeben et al. A comparison of clinical and radiological outcomes of four treatment strategies for early rheumatoid arthritis: Results of the Best trial Ann Rheum Dis 63 supplement 1 2004 58
94. J.S. Smolen P. Emery J. Bathon et al. Treatment of early rheumatoid arthritis with infliximab plus methotrexate or methotrexate alone: preliminary results of the ASPIRE trial Ann Rheum Dis 62 supplement 1 2003 0001
95. M.E. Weinblatt Rheumatoid arthritis in : Where are we now with treatment? Ann Rheum Dis 62 supplement ii 2003 ii94-ii96
96. J.S. Smolen T. Sokka T. Pincus F.C. Breedveld A proposed treatment algorithm for rheumatoid arthritis: Aggressive therapy, methotrexate, and quantitative measures Clin Exp Rheumatol 21 supplement 31 2003 S209-S210
97. C. Grigor H.A. Capell A. Stirling et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial Lancet 364 2004 263-269
98. D. Aletaha J.S. Smolen Patients with rheumatoid arthritis in clinical care Ann Rheum Dis 63 2004 221-225
99. D. Aletaha J.S. Smolen DMARD use in early rheumatoid arthritis. Lessons from observations in patients with established disease Clin Exp Rheumatol 21 supplement 31 2003 S169-S173
100. D. Aletaha J.S. Smolen Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study J Rheumatol 2002 29
101. T. Pincus Y. Yazici T. Sokka et al. Methotrexate as the 'anchor drug' for the treatment of early rheumatoid arthritis Clin Exp Rheumatol 21 supplement 31 2003 S178-S185
102. K.P. Machold V.P. Nell T.A. Stamm et al. The Austrian Early Arthritis Registry Clin Exp Rheumatol 21 supplement 31 2003 S113-S117